KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Inventory (2020 - 2025)

Esperion Therapeutics (ESPR) has disclosed Inventory for 6 consecutive years, with $105.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Inventory rose 11.25% year-over-year to $105.1 million, compared with a TTM value of $105.1 million through Dec 2025, up 11.25%, and an annual FY2025 reading of $105.1 million, up 11.25% over the prior year.
  • Inventory was $105.1 million for Q4 2025 at Esperion Therapeutics, down from $108.5 million in the prior quarter.
  • Across five years, Inventory topped out at $114.5 million in Q2 2025 and bottomed at $20.0 million in Q1 2021.
  • Average Inventory over 5 years is $60.2 million, with a median of $48.6 million recorded in 2023.
  • The sharpest move saw Inventory skyrocketed 988.0% in 2021, then dropped 13.03% in 2022.
  • Year by year, Inventory stood at $34.4 million in 2021, then increased by 2.35% to $35.2 million in 2022, then skyrocketed by 86.42% to $65.6 million in 2023, then skyrocketed by 43.99% to $94.5 million in 2024, then grew by 11.25% to $105.1 million in 2025.
  • Business Quant data shows Inventory for ESPR at $105.1 million in Q4 2025, $108.5 million in Q3 2025, and $114.5 million in Q2 2025.